Outlook Therapeutics, Inc. (NASDAQ:OTLK) traded at $1.29 at last check on Tuesday, Jun 30, making an upward move of 3.2% on its previous day’s price.

Looking at the stock we see that its previous close was $1.25 and the beta (5Y monthly) reads 0.31 with the day’s price range being $1.2400 – 1.3000. In terms of its 52-week price range, OTLK has a high of $2.89 and a low of $0.499. The company’s stock has gained about 15.18% over that past 30 days.

On the other hand, looking at the outlook for the OTLK stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 5 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Outlook Therapeutics, Inc. (OTLK) stock as a Hold, while 5 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the OTLK stock currently stands at 0, and the current price level is 5.78% off its SMA20 and 36.47% from its 50-day simple moving average. The RSI (14) is pointing at 58.76 while the volatility over the past week is 10.11% and jumps to 12.5% over the past one month. The beta value is 0.33, while the average true range (ATR) is currently pointing at 0.14. The average price target for the stock over the next 12 months is $6.05, with the estimates having a low of $3.25 and a high of $9. These price ends are 151.94% and +597.67% off the current price level respectively, although investors could be excited at the prospect of a +365.12% if the OTLK share price touches on the median price of $6.

Let’s briefly compare Outlook (OTLK) stock to its peers. We find that today’s price change of +3.2% and -38.28% over the past 12 months for OTLK competes that of Amgen Inc (AMGN), which has seen its stock price rise 1.86% in the latest trading session and is +26.57% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 3.19% today, and is +13.43% up over the past year, while Vertex Pharmaceutic (VRTX) is also up 3.2% yet its price remains in the red at -38.28% over the same period. Amgen has a P/E ratio of 18.48 compared to Outlook’s 0 and Gilead’s 19.78. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.85% and 1.54%, respectively, in early deals.

Coming back to Outlook Therapeutics, Inc. (NASDAQ:OTLK), we note that the average 3-month trading volume was 2.07 Million, while that of the preceding 10-day period stands at 7.62 Million. Current shares outstanding are 122.34 Million.